Prevention of Myopia of Prematurity by Calcium Supplementation
Primary Purpose
Myopia
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Calcium Supplementation
Standard of Care
Sponsored by
About this trial
This is an interventional prevention trial for Myopia focused on measuring myopia, calcium supplementation, prematurity
Eligibility Criteria
Inclusion Criteria:
- Infants with a birthweight of 401 - 1000 g and postnatal age less than 14 days
Exclusion Criteria:
Major congenital malformations including
- complex congenital heart disease (except open ductus arteriosus, atrial and ventricular septal defects)
- pulmonary malformations
- bowel or anal stenosis or atresia
- renal dysplasias
- chromosomal anomalies
- hydrops fetalis
- bowel perforation or necrotizing enterocolitis stage 2A or greater before randomization.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
1
2
Arm Description
Infants receive supplemental calcium in their 24 cal/oz formula or fortified breast milk.
Infants will receive fortified breast milk or 24 cal/oz formula
Outcomes
Primary Outcome Measures
Supplementation of Ca by the enteral route to ELBW infants will lead to an increased cycloplegic refraction at 6-12 months postnatal age.
Secondary Outcome Measures
Supplementation of Ca will lead to increased cycloplegic refraction at 18-22 months corrected age.
Supplementation of Ca will lead to an increased cycloplegic refraction at 6-12 months postnatal age and at 18-22 months corrected age in infants who had no abdominal surgery or prolonged feeding intolerance
Supplementation of Ca will reduce the dolichocephalic deformation of the infants' heads as measured by the FOD/BPD index.
Supplementation of Ca will reduce the incidence of fractures.
Supplementation of Ca will not increase the incidence of NEC stage 2A or greater.
Supplementation of Ca will not increase the incidence of feeding intolerance.
Supplementation of Ca is not associated with a change in the incidence of ROP.
Supplementation of Ca will increase bone mineral density at 36 weeks postmenstrual age (only relevant if measurement is available).
Full Information
NCT ID
NCT00892476
First Posted
April 30, 2009
Last Updated
December 4, 2012
Sponsor
University of Alabama at Birmingham
1. Study Identification
Unique Protocol Identification Number
NCT00892476
Brief Title
Prevention of Myopia of Prematurity by Calcium Supplementation
Official Title
Prevention of Myopia of Prematurity by Calcium Supplementation in a Randomized Controlled Pilot Trial
Study Type
Interventional
2. Study Status
Record Verification Date
July 2010
Overall Recruitment Status
Completed
Study Start Date
February 2002 (undefined)
Primary Completion Date
June 2004 (Actual)
Study Completion Date
December 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Alabama at Birmingham
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine if supplementation of calcium by the enteral route (gut feeding) to extremely low birth weight infants will lead to less myopia (nearsightedness) at 6-12 months postnatal age.
Secondly, the study will determine if calcium supplementation is well tolerated, if it reduces the molding of these premature infants' heads, and if it decreases myopia at the 18-22 month postnatal age visit.
Detailed Description
All infants admitted meeting the 401-1000gm birthweight and less than 14 day of age entry criteria will be screened for entry into the study. Infants may be excluded for the following: Major congenital malformations, including complex congenital heart disease (except open ductus arteriosus, atrial and ventricular septal defects), pulmonary malformations, bowel or anal stenosis or atresia, renal dysplasias, chromosomal anomalies, hydrops fetalis, bowel perforation or necrotizing enterocolitis stage 2A or greater before randomization.
Written informed consent of one parent or legal guardian must be obtained. The infants are randomized to receive unsupplemented feedings of breast milk or formula, or feedings supplemented with Ca-gluconate as outlined below.
Randomization will be stratified into the following groups: 401-750 g and 751-1000 g and performed according to a balanced block scheme with variable block size (2-6) using sealed opaque envelopes.
Total parenteral nutrition is given by nursery unit standards. Infant positioning is done by nursery unit standards.
Feeding mixtures:
Supplementation is started when enteral feeding amounts to 100 ml/kg. At that time, fortification is also introduced in infants receiving breast milk. Fortified human milk or 24 cal/oz formula, e.g. Similac Special Care 24 (SSC24), is used in all participating infants. Human milk is fortified with 1 pk Enfamil human milk fortifier per 25 ml (BMHMF).
Control group: Fortified human milk or 24 cal/oz formula. Supplemented group: Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons (e.g. Rubbermaid (R)) and added to the feeding mixtures.
One eye exam will be performed at 6-12 months during routine follow-up visit. A second eye exam will be performed at 18-2 months during a follow-up visit which is part of the NICHD newborn follow-up clinic. Head measurements, specifically, front-to-back and side-to-side will be measured at randomization, 36 weeks postmenstrual age or discharge, whichever occurs first, and during the follow up visits. Urinalysis will be collected weekly.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myopia
Keywords
myopia, calcium supplementation, prematurity
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
99 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Infants receive supplemental calcium in their 24 cal/oz formula or fortified breast milk.
Arm Title
2
Arm Type
Active Comparator
Arm Description
Infants will receive fortified breast milk or 24 cal/oz formula
Intervention Type
Dietary Supplement
Intervention Name(s)
Calcium Supplementation
Other Intervention Name(s)
USP grade Calcium gluconate powder from Sigma Chemical Company (Cat # C-8231, St. Louis, MO)
Intervention Description
Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons and added to the feeding mixtures as follows:
Amount of feeding Actual Weight < 1000 g Actual Weight < 1000 g
25 ml ¼ tsp 1/8 tsp
50 ml ½ tsp ¼ tsp
100 ml 1 tsp ½ tsp
200 ml 2 tsp 1 tsp
Intervention Type
Other
Intervention Name(s)
Standard of Care
Intervention Description
Infants are feed breast milk with fortifier or 24 cal/oz formula per standard of care
Primary Outcome Measure Information:
Title
Supplementation of Ca by the enteral route to ELBW infants will lead to an increased cycloplegic refraction at 6-12 months postnatal age.
Time Frame
6-12 months postnatal age
Secondary Outcome Measure Information:
Title
Supplementation of Ca will lead to increased cycloplegic refraction at 18-22 months corrected age.
Time Frame
18-22 months corrected age
Title
Supplementation of Ca will lead to an increased cycloplegic refraction at 6-12 months postnatal age and at 18-22 months corrected age in infants who had no abdominal surgery or prolonged feeding intolerance
Time Frame
6 months postnatal age to 18-22 months corrected age
Title
Supplementation of Ca will reduce the dolichocephalic deformation of the infants' heads as measured by the FOD/BPD index.
Time Frame
18-22 months corrected age
Title
Supplementation of Ca will reduce the incidence of fractures.
Time Frame
birth to discharge
Title
Supplementation of Ca will not increase the incidence of NEC stage 2A or greater.
Time Frame
birth to discharge
Title
Supplementation of Ca will not increase the incidence of feeding intolerance.
Time Frame
birth to discharge
Title
Supplementation of Ca is not associated with a change in the incidence of ROP.
Time Frame
birth to full vascularization of the retina
Title
Supplementation of Ca will increase bone mineral density at 36 weeks postmenstrual age (only relevant if measurement is available).
Time Frame
36 weeks postmenstrual age
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
14 Days
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Infants with a birthweight of 401 - 1000 g and postnatal age less than 14 days
Exclusion Criteria:
Major congenital malformations including
complex congenital heart disease (except open ductus arteriosus, atrial and ventricular septal defects)
pulmonary malformations
bowel or anal stenosis or atresia
renal dysplasias
chromosomal anomalies
hydrops fetalis
bowel perforation or necrotizing enterocolitis stage 2A or greater before randomization.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Waldemar Carlo, MD
Organizational Affiliation
University of Alabama at Birmingham
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
21865980
Citation
Carroll WF, Fabres J, Nagy TR, Frazier M, Roane C, Pohlandt F, Carlo WA, Thome UH. Results of extremely-low-birth-weight infants randomized to receive extra enteral calcium supply. J Pediatr Gastroenterol Nutr. 2011 Sep;53(3):339-45. doi: 10.1097/MPG.0b013e3182187ecd.
Results Reference
derived
Learn more about this trial
Prevention of Myopia of Prematurity by Calcium Supplementation
We'll reach out to this number within 24 hrs